Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Daiichi Sankyo
Colorcon
Julphar
Healthtrust
Teva

Generated: August 24, 2019

DrugPatentWatch Database Preview

Patent: 8,217,035

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,217,035
Title:Pyrimidine derivatives used as PI-3-kinase inhibitors
Abstract: Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases. ##STR00001##
Inventor(s): Burger; Matthew (Emeryville, CA), Ni; Zhi-Jie (Emeryville, CA), Pecchi; Sabina (Emeryville, CA), Atallah; Gordana (Emeryville, CA), Bartulis; Sarah (Emeryville, CA), Frazier; Kelly (Emeryville, CA), Smith; Aaron (Emeryville, CA), Verhagen; Joelle (Emeryville, CA), Zhang; Yanchen (Emeryville, CA), Wagman; Allan (Emeryville, CA), Ng; Simon (Emeryville, CA), Pfister; Keith (Emeryville, CA), Poon; Daniel (Emeryville, CA), Louie; Alicia (Emeryville, CA), Pick; Teresa (Emeryville, CA), Barsanti; Paul (Emeryville, CA), Iwanowicz; Edwin (Emeryville, CA), Fantl; Wendy (Emeryville, CA), Hendrickson; Thomas (Emeryville, CA), Knapp; Mark (Emeryville, CA), Merritt; Hanne (Emeryville, CA), Voliva; Charles (Emeryville, CA), Wiesmann; Marion (Emeryville, CA), Xin; Xiaohua (Emeryville, CA)
Assignee: Novartis AG (Basel, CH)
Application Number:12/161,537
Patent Claims:see list of patent claims

Details for Patent 8,217,035

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech PERJETA pertuzumab VIAL; SINGLE-USE 125409 001 2012-06-08 ➤ Sign Up Novartis AG (Basel, CH) 2036-04-30 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26 ➤ Sign Up Novartis AG (Basel, CH) 2036-04-30 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26 ➤ Sign Up Novartis AG (Basel, CH) 2036-04-30 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cantor Fitzgerald
Daiichi Sankyo
QuintilesIMS
AstraZeneca
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.